{
  "meta": {
    "title": "Medicine_Mini_Test_6_Endocrinology",
    "url": "https://brainandscalpel.vercel.app/medicine-mini-test-6-endocrinology-5d957908.html",
    "scrapedAt": "2025-11-30T07:32:43.849Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased insulin sensitivity</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Enhanced glycolysis</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Fatty acid oxidation</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased gluconeogenesis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In Diabetic Ketoacidosis (DKA), which of the following biochemical processes is primarily responsible for the production of ketone bodies?</span></p>",
      "unique_key": "Q240606",
      "question_audio": null,
      "question_video": null,
      "map_id": 240606,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p>In <strong>Diabetic Ketoacidosis (DKA)</strong>, the lack of insulin leads to <strong>increased lipolysis</strong> (breakdown of fats) in adipose tissue. This increases the availability of <strong>free fatty acids</strong>, which are transported to the liver and undergo <strong>beta-oxidation</strong> to produce <strong>acetyl-CoA</strong>. The excess acetyl-CoA cannot enter the citric acid cycle (due to oxaloacetate depletion, as it is diverted to gluconeogenesis), so it is shunted into the production of <strong>ketone bodies</strong> (<strong>acetoacetate, beta-hydroxybutyrate</strong>, and <strong>acetone</strong>). These ketones lead to the metabolic acidosis characteristic of DKA.</p><p><strong>Option A: Increased insulin sensitivity:</strong> DKA occurs due to a <strong>lack of insulin</strong> or severe <strong>insulin resistance</strong>, so insulin sensitivity is actually <strong>reduced</strong>. Low insulin levels trigger lipolysis and ketogenesis, the opposite of increased insulin sensitivity.</p><p><strong>Option B: Enhanced glycolysis:</strong> In DKA, <strong>glycolysis</strong> is reduced because the body is unable to utilize glucose properly due to the lack of insulin. Instead, glucose builds up in the blood (hyperglycemia), and alternative energy sources, such as fatty acids, are used.</p><p><strong>Option C: Fatty acid oxidation: Fatty acid oxidation</strong> is the primary process responsible for the production of ketone bodies in DKA. This occurs due to insulin deficiency, which stimulates lipolysis and the conversion of fatty acids into ketones in the liver.</p><p><strong>Option D: Increased gluconeogenesis: Gluconeogenesis</strong> is increased in DKA due to insulin deficiency and counterregulatory hormones (glucagon, cortisol), leading to hyperglycemia. However, this process contributes to the hyperglycemia seen in DKA, not the production of ketones. The ketone production comes primarily from fatty acid oxidation.</p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/1E.jpg\"><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/1E1.jpg\"><p><strong>Key Features of DKA Pathophysiology:</strong></p><ul><li><strong>Insulin deficiency</strong> leads to increased <strong>lipolysis</strong>, releasing free fatty acids.</li><li><strong>Fatty acid oxidation</strong> in the liver produces ketone bodies.</li><li><strong>Ketone bodies</strong> (acetoacetate, beta-hydroxybutyrate) cause metabolic acidosis.</li><li><strong>Gluconeogenesis</strong> and glycogenolysis increase, contributing to severe hyperglycemia.</li></ul><p><strong>Tags:</strong></p><p><strong>Topic:</strong> Diabetic ketoacidosis</p><p><strong>Difficulty Level:</strong> Must know</p><p><strong>PYQ:</strong> FMGE 2021,2022,2023/NEET 2022,2023/</p><p><strong>Reference:</strong> Harrison's 21<sup>st</sup> edition, principles of internal medicine, page number 3115</p>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Primary hyperparathyroidism</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Malignancy-associated hypercalcemia</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Familial hypocalciuric hypercalcemia</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Vitamin D toxicity</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old woman presents with fatigue, abdominal pain, and confusion. Her past medical history includes nephrolithiasis. On physical examination, she has mild dehydration, reduced deep tendon reflexes, and no palpable masses. Laboratory tests reveal the following: <br>Serum calcium: 12.8 mg/dL (normal: 8.5-10.2 mg/dL)<br>Serum phosphate: 2.0 mg/dL (normal: 2.5-4.5 mg/dL)<br>Parathyroid hormone (PTH): elevated<br>Serum creatinine: 1.6 mg/dL (baseline 1.1 mg/dL)<br>24-hour urine calcium: increased<br><br>What is the most likely cause of her hypercalcemia?</span></p>",
      "unique_key": "Q240607",
      "question_audio": null,
      "question_video": null,
      "map_id": 240607,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p><strong>Primary hyperparathyroidism (PHPT):</strong> The patient's elevated <strong>calcium</strong> level, low <strong>phosphate</strong>, elevated <strong>PTH</strong>, and increased <strong>urinary calcium excretion</strong> are all classic signs of <strong>primary hyperparathyroidism</strong>. This condition is most commonly due to a <strong>parathyroid adenoma</strong> that overproduces PTH, leading to excessive calcium reabsorption from bones, increased intestinal calcium absorption, and decreased renal excretion of calcium.</p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/2E4.jpg\"><p><strong>Symptoms</strong> of <strong>hypercalcemia</strong> include <strong>fatigue, abdominal pain, confusion, nephrolithiasis</strong>, and <strong>dehydration</strong>. The elevated PTH levels differentiate PHPT from other causes of hypercalcemia.</p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/2E1.jpg\"><p><strong>Option A: Primary hyperparathyroidism:</strong> The hallmark of <strong>primary hyperparathyroidism</strong> is elevated PTH in the presence of <strong>hypercalcemia</strong> and <strong>hypophosphatemia</strong>. Increased <strong>urinary calcium excretion</strong> helps differentiate it from familial hypocalciuric hypercalcemia. The most common cause is a <strong>parathyroid adenoma</strong>.</p><p><strong>Option B: Malignancy-associated hypercalcemia: Hypercalcemia of malignancy</strong> is usually caused by <strong>parathyroid hormone-related peptide (PTHrP)</strong> secretion or bone metastasis. In these cases, PTH levels are usually <strong>low</strong> due to negative feedback, making it less likely in this case. Additionally, the patient has no known cancer history or significant weight loss.</p><p><strong>Option C: Familial hypocalciuric hypercalcemia:</strong> Familial hypocalciuric hypercalcemia (FHH) presents with <strong>mildly elevated calcium</strong> and <strong>low urinary calcium excretion</strong> (hypocalciuria), unlike this patient, who has <strong>increased urinary calcium excretion</strong>. FHH is typically benign and does not require treatment.</p><p><strong>Option D: Vitamin D toxicity:</strong> Vitamin D toxicity leads to <strong>hypercalcemia</strong> due to excessive intestinal calcium absorption. In such cases, PTH is typically <strong>low</strong>, and <strong>phosphate</strong> levels are <strong>elevated</strong>, which is not seen in this patient.</p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/2E2.jpg\"><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/2E3.jpg\"><p><strong>Key Takeaway:</strong></p><p><strong>Primary hyperparathyroidism</strong> is the most common cause of <strong>hypercalcemia</strong> in ambulatory patients. It is characterized by <strong>elevated PTH, hypercalcemia</strong>, and <strong>low phosphate</strong> levels. Symptoms often include <strong>nephrolithiasis, bone pain</strong>, and <strong>gastrointestinal disturbances</strong>.</p><p>The symptoms of <strong>hypercalcemia</strong>:</p><p><strong>\"Stones, Bones, Groans, Thrones, and Psychiatric Overtones\"</strong></p><ul><li><strong>Stones:</strong> Refers to <strong>kidney stones</strong> (nephrolithiasis) due to hypercalciuria.</li><li><strong>Bones: Bone pain</strong> and <strong>osteopenia/osteoporosis</strong> due to calcium being pulled from the bones.</li><li><strong>Groans:</strong> Refers to <strong>abdominal pain, constipation, nausea</strong>, and <strong>vomiting</strong> due to gastrointestinal effects.</li><li><strong>Thrones:</strong> Increased <strong>urination</strong> and <strong>dehydration</strong> due to hypercalcemia's effect on the kidneys (nephrogenic diabetes insipidus).</li><li><strong>Psychiatric Overtones: Confusion, lethargy, fatigue, depression</strong>, and <strong>cognitive dysfunction</strong> due to the effects on the central nervous system.</li></ul><p><strong>Tags:</strong></p><p><strong>Topic:</strong> Hypercalcemia</p><p><strong>Difficulty Level:</strong> May know</p><p><strong>PYQ:</strong> FMGE 2023/INI CET 2022</p><p><strong>Reference:</strong> Harrison's 21<sup>st</sup> edition, principles of internal medicine, page number: 3511</p>",
      "correct_choice_id": 11,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">MEN 1 Syndrome</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">MEN 2A Syndrome</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">MEN 2B Syndrome</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Familial Medullary Thyroid Carcinoma (FMTC)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 30-year-old man presents with a history of chronic diarrhea, mouth sores, and a family history of thyroid cancer. On examination, he has mucosal neuromas on the lips and tongue, and a marfanoid body habitus. Genetic testing reveals a RET proto-oncogene mutation. Which of the following is the most likely diagnosis?</span></p>",
      "unique_key": "Q240608",
      "question_audio": null,
      "question_video": null,
      "map_id": 240608,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p><strong>Option A: MEN 1 Syndrome</strong></p><p><strong>MEN 1 Syndrome</strong> involves <strong>parathyroid adenomas, pituitary tumors</strong>, and <strong>pancreatic tumors</strong>. This patient's presentation with <strong>mucosal neuromas, marfanoid habitus</strong>, and a family history of <strong>thyroid cancer</strong> suggests <strong>MEN 2B</strong>, not MEN 1.</p><p><strong>Option B: MEN 2A Syndrome</strong></p><p><strong>MEN 2A Syndrome</strong> includes <strong>medullary thyroid carcinoma (MTC)</strong>, <strong>pheochromocytoma</strong>, and <strong>parathyroid hyperplasia</strong>, but <strong>mucosal neuromas</strong> and <strong>marfanoid habitus</strong> are not features of MEN 2A. <strong>MEN 2B</strong> involves <strong>MTC</strong> and <strong>pheochromocytoma</strong>, but also includes these distinct features.</p><p><strong>Option C: MEN 2B Syndrome</strong></p><p><strong>MEN 2B Syndrome</strong> is characterized by <strong>medullary thyroid carcinoma (MTC)</strong>, <strong>pheochromocytoma, mucosal neuromas</strong>, and a <strong>marfanoid habitus</strong>. The patient's presentation with <strong>chronic diarrhea</strong> (related to MTC), <strong>mucosal neuromas</strong>, and a <strong>marfanoid habitus</strong>, along with a <strong>RET mutation</strong>, strongly points to <strong>MEN 2B</strong>.</p><ul><li><strong>Medullary Thyroid Carcinoma (MTC):</strong> A neuroendocrine tumor of the thyroid gland, often presenting with <strong>diarrhea</strong> due to hormone secretion.</li><li><strong>Pheochromocytoma:</strong> An adrenal tumor that secretes catecholamines, causing <strong>hypertension, headaches</strong>, and <strong>sweating</strong>.</li><li><strong>Mucosal Neuromas:</strong> Benign nerve tumors typically found on the lips, tongue, and gastrointestinal tract.</li><li><strong>Marfanoid Habitus:</strong> A body shape resembling <strong>Marfan syndrome</strong>, with tall stature, long limbs, and hyperextensibility of joints.</li><li><strong>RET Mutation:</strong> Genetic mutation in the <strong>RET proto-oncogene</strong>, responsible for the development of MEN 2B.</li></ul><p><strong>Option D: Familial Medullary Thyroid Carcinoma (FMTC)</strong></p><p><strong>FMTC</strong> is a variant of <strong>MEN 2A</strong> and involves <strong>medullary thyroid carcinoma (MTC)</strong> without pheochromocytomas or parathyroid involvement. This patient has additional features such as <strong>mucosal neuromas</strong> and <strong>marfanoid habitus</strong>, which are characteristic of <strong>MEN 2B</strong>, not FMTC.</p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/3E.jpg\"><p><strong>Mnemonic for MEN 2B Features:</strong></p><p><strong>\"MTC, Marfanoid, Mucosal Neuromas\":</strong></p><ul><li><strong>MTC:</strong> Medullary Thyroid Carcinoma</li><li><strong>M:</strong> Marfanoid habitus</li><li><strong>M:</strong> Mucosal neuromas</li></ul><p><strong>Tags:</strong></p><p><strong>Topic:</strong> Endocrinology, MEN Syndromes</p><p><strong>Difficulty Level:</strong> May Know</p><p><strong>PYQ:</strong> NEET 2022, FMGE2020, INICET</p><p><strong>Reference:</strong> Harrison's Principles of Internal Medicine, 21st Edition, Page Number:2984</p>",
      "correct_choice_id": 23,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Elevated Thyroglobulin levels</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Positive Anti-thyroglobulin antibodies</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Positive TSH receptor antibodies (TRAbs)</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">All of above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 36-year-old woman presents with weight loss, tremors, palpitations, and heat intolerance. On physical examination, she has a diffusely enlarged thyroid gland with a bruit, and her eyes are noted to be prominent with limited upward gaze. Her lab results show suppressed TSH and elevated free T4. Radioactive iodine uptake shows diffuse uptake. Which of the following laboratory findings would further confirm the diagnosis of Grave's disease?</span></p>",
      "unique_key": "Q240609",
      "question_audio": null,
      "question_video": null,
      "map_id": 240609,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p><strong>Option C. Positive TSH receptor antibodies (TRAbs)</strong> are specific to <strong>Grave's disease.</strong> These antibodies stimulate the thyroid gland by binding to TSH receptors, causing overproduction of thyroid hormones (hyperthyroidism). TRAbs are highly specific for Grave's disease and help distinguish it from other causes of hyperthyroidism, such as toxic multinodular goiter or thyroiditis.</p><p><strong>Option A: Elevated Thyroglobulin levels</strong></p><p><strong>Thyroglobulin levels</strong> are elevated in various conditions that cause thyroid overactivity or destruction of thyroid tissue, including <strong>thyroiditis, Grave's disease</strong>, and <strong>thyroid cancer</strong>.</p><p>Elevated thyroglobulin is non-specific and not helpful in confirming Grave's disease.</p><p><strong>Option B: Positive Anti-thyroglobulin antibodies</strong></p><p><strong>Anti-thyroglobulin antibodies</strong> are also seen in <strong>autoimmune thyroid diseases</strong>, including <strong>Hashimoto's thyroiditis</strong> and <strong>Grave's disease</strong>, but they are not specific.</p><p>They indicate thyroid tissue damage and are not used to confirm the diagnosis of <strong>Grave's disease</strong> specifically.</p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/4E.jpg\"><p><strong>Key Features of Grave's Disease</strong>:</p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/4E1.jpg\"><p><strong>Mnemonic for Grave's Disease Diagnosis:</strong></p><p><strong>\"GREAT\":</strong></p><ul><li><strong>G: Grave's disease</strong>.</li><li><strong>R: Radioactive iodine uptake</strong> (diffuse).</li><li><strong>E: Exophthalmos</strong>.</li><li><strong>A: Antibodies</strong> (TSH receptor antibodies).</li><li><strong>T: Thyroid enlargement</strong> with <strong>bruit</strong>.</li></ul><p><strong>Key Takeaway:</strong></p><p><strong>TSH receptor antibodies (TRAbs)</strong> are specific for <strong>Grave's disease</strong> and help confirm the diagnosis in patients with hyperthyroidism.</p><p><strong>Tags:</strong></p><p><strong>Topic:</strong> Endocrinology, Thyroid Disorders, Grave's Disease</p><p><strong>Difficulty Level:</strong> May know</p><p><strong>PYQ:</strong> FMGE 2021, INICET 2022</p><p><strong>Reference:</strong> Harrison's Principles of Internal Medicine, 21st Edition, Page Number 2932</p>",
      "correct_choice_id": 33,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Gigantism</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Acromegaly</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Cushing's syndrome</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypothyroidism</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old man presents with progressive enlargement of his hands, feet, and facial features. He complains of joint pain, headaches, and excessive sweating. On examination, the patient has coarse facial features, a prominent jaw, and enlarged hands and feet. Laboratory tests reveal elevated levels of insulin-like growth factor 1 (IGF-1) and an abnormal glucose suppression test. What is the most likely diagnosis?</span></p>",
      "unique_key": "Q240610",
      "question_audio": null,
      "question_video": null,
      "map_id": 240610,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p><strong>Option A: Gigantism</strong></p><p><strong>Gigantism</strong> occurs in children or adolescents before the closure of the epiphyseal growth plates due to excessive growth hormone (GH).</p><p>This leads to excessive linear growth (height), which is different from the <strong>acromegaly</strong> seen in adults where growth plates have closed. The patient in this case is an adult, ruling out gigantism.</p><p><strong>Option B: Acromegaly</strong></p><p><strong>Acromegaly</strong> is caused by excessive secretion of growth hormone, usually due to a <strong>pituitary adenoma</strong>.</p><p>In adults, this leads to <strong>enlargement of bones</strong> (hands, feet, jaw) and soft tissues, causing the distinctive physical changes. Other symptoms include <strong>headaches, joint pain</strong>, and <strong>excessive sweating</strong>.</p><p>The <strong>elevated IGF-1 levels</strong> and the <strong>failure of GH to suppress after an oral glucose tolerance test</strong> confirm the diagnosis. Additionally, patients may have comorbidities like <strong>hypertension</strong>, <strong>diabetes mellitus</strong>, and <strong>sleep apnea</strong>.</p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/5E.jpg\"><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/5E1.jpg\"><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/5E2.jpg\"><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/5E3.jpg\"><p><strong>Option C: Cushing's syndrome</strong></p><p><strong>Cushing's syndrome</strong> is caused by prolonged exposure to excess cortisol.</p><p>Symptoms include <strong>weight gain, moon face, buffalo hump, abdominal striae</strong>, and <strong>muscle weakness</strong>, which are not present in this patient.</p><p>Cushing's does not present with the characteristic <strong>enlargement of hands, feet, and jaw</strong> seen in acromegaly.</p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/5E4.jpg\"><p><strong>Option D: Hypothyroidism</strong></p><p><strong>Hypothyroidism</strong> can cause <strong>weight gain, fatigue, cold intolerance</strong>, and <strong>dry skin</strong>.</p><p>However, it does not cause the characteristic <strong>bony and soft tissue changes</strong> seen in acromegaly.</p><p>Additionally, hypothyroidism typically presents with <strong>low thyroid hormone levels</strong>, not elevated IGF-1 or abnormal GH suppression.</p><p><strong>Key Diagnostic Features of Acromegaly:</strong></p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/5E5.jpg\"><p><strong>Key Points:</strong></p><ul><li>Acromegaly is diagnosed through <strong>elevated IGF-1 levels</strong> and an abnormal <strong>oral glucose suppression test</strong>.</li><li>Common <strong>symptoms</strong> include <strong>enlarged hands, feet, jaw</strong>, joint pain, and headaches.</li><li><strong>Transsphenoidal surgery</strong> is the main treatment for pituitary adenomas causing acromegaly.</li></ul><p><strong>Tags:</strong></p><ul><li><strong>Topic:</strong> Endocrinology:Acromegaly Diagnosis and Treatment</li><li><strong>Difficulty Level:</strong> May Know</li><li>FMGE 2020,2023 NEET 2022</li></ul><p><strong>Reference:</strong> Harrison's principles of internal medicine, 21<sup>st</sup> edition, Page Number 2904</p>",
      "correct_choice_id": 42,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Diabetic retinopathy</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Diabetic nephropathy</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Coronary artery disease</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Diabetic neuropathy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old man with a 15-year history of type 2 diabetes mellitus presents with decreased vision, proteinuria, and intermittent chest pain. His blood pressure is 150/90 mmHg, and his HbA1c is 9%. Which of the following is a macrovascular complication of diabetes in this patient?</span></p>",
      "unique_key": "Q240611",
      "question_audio": null,
      "question_video": null,
      "map_id": 240611,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p><strong>Option A: Diabetic Retinopathy</strong></p><p>Diabetic retinopathy is a <strong>microvascular complication</strong> of diabetes and is caused by damage to the small blood vessels of the retina due to prolonged hyperglycemia. It is not a macrovascular complication.</p><p><strong>Option B: Diabetic Nephropathy</strong></p><p>Diabetic nephropathy is also a <strong>microvascular complication</strong>. It is characterized by damage to the kidney's glomeruli, leading to proteinuria and, over time, progressive renal dysfunction. It is not classified as a macrovascular complication.</p><p><strong>Option C: Coronary Artery Disease (CAD)</strong></p><p>Coronary artery disease is a <strong>macrovascular complication</strong>.</p><p>Diabetes significantly increases the risk of atherosclerosis and cardiovascular diseases, including myocardial infarction and stroke, due to its effects on large blood vessels (macrovascular).</p><p>This patient's intermittent chest pain suggests coronary artery involvement, which is common in long-standing diabetes.</p><p><strong>Option D: Diabetic Neuropathy</strong></p><p>Diabetic neuropathy is a <strong>microvascular complication</strong> resulting from nerve damage caused by poor blood flow and elevated glucose levels.</p><p>It typically affects the peripheral nerves, leading to sensory and motor deficits. Like diabetic retinopathy and nephropathy, it is not a macrovascular complication.</p><p>Key Takeaway:</p><ul><li><strong>Macrovascular complications</strong> of diabetes include coronary artery disease, cerebrovascular disease (stroke), and peripheral arterial disease, whereas <strong>microvascular complications</strong> include diabetic retinopathy, nephropathy, and neuropathy.</li></ul><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/6E.jpg\"><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/6E2.jpg\"><p><strong>Tags:</strong></p><p><strong>Topic:</strong> Complications of Diabetes Mellitus</p><p><strong>Difficulty Level:</strong> Must know</p><p><strong>PYQ:</strong> FMGE 2020 NEET 2022 2023</p><p><strong>Reference:</strong> Harrison's principles of internal medicine, 21<sup>st</sup> edition, Page Number 3120</p>",
      "correct_choice_id": 53,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Hemochromatosis</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Wilson's disease</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Autoimmune hepatitis</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Alpha-1 antitrypsin deficiency</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 15-year-old boy presents with progressive tremors, slurred speech, and jaundice. He has had difficulty in school due to deteriorating motor control and psychiatric symptoms. Physical examination reveals a golden-brown ring around the cornea. Laboratory tests show elevated liver enzymes, decreased serum ceruloplasmin, and increased urinary copper excretion. What is the most likely diagnosis?</span></p>",
      "unique_key": "Q240612",
      "question_audio": null,
      "question_video": null,
      "map_id": 240612,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p><strong>Option A: Hemochromatosis</strong></p><p>Hemochromatosis is a disorder of <strong>iron overload</strong>, leading to iron deposition in various organs, particularly the liver, heart, and pancreas.</p><p>It presents with symptoms such as <strong>diabetes, skin hyperpigmentation, liver cirrhosis</strong>, and cardiomyopathy. Unlike Wilson's disease, <strong>neurological symptoms</strong> like tremors and psychiatric disturbances are not common in hemochromatosis, and it does not cause a <strong>Kayser-Fleischer ring</strong> (the golden-brown ring around the cornea).</p><p>In addition, lab findings would show <strong>elevated serum iron, ferritin, and transferrin saturation</strong> in hemochromatosis, not the copper abnormalities seen in Wilson's disease.</p><p><strong>Option B: Wilson's disease</strong></p><p>Wilson's disease is an <strong>autosomal recessive disorder</strong> of <strong>copper metabolism</strong> caused by mutations in the <strong>ATP7B gene</strong>, leading to defective excretion of copper into bile and accumulation in tissues such as the liver, brain, and eyes.</p><p>Clinical features of Wilson's disease often manifest in <strong>adolescence</strong> and include:</p><ul><li><strong>Neurological symptoms</strong> (tremors, dysarthria, dystonia, and Parkinsonism)</li><li><strong>Psychiatric disturbances</strong> (depression, personality changes)</li><li><strong>Hepatic dysfunction</strong> (jaundice, liver failure)</li><li><strong>Kayser-Fleischer rings</strong> (copper deposition in the cornea), which are characteristic of Wilson's disease and are often detected on slit-lamp examination.</li></ul><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/7E.jpg\"><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/7E1.jpg\"><p><strong>Kayser-Fleischer rings (KF rings)</strong></p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/7E3.jpg\"><p>Laboratory findings show:</p><ul><li><strong>Decreased serum ceruloplasmin</strong></li><li><strong>Increased urinary copper excretion</strong></li><li><strong>Elevated liver enzymes</strong> due to hepatic injury</li></ul><p>The combination of <strong>neurological symptoms, Kayser-Fleischer rings</strong>, and <strong>abnormal copper metabolism</strong> makes Wilson's disease the most likely diagnosis in this case.</p><p><strong>Option C: Autoimmune hepatitis</strong></p><p>Autoimmune hepatitis presents with liver dysfunction and elevated liver enzymes, and it typically affects young women more than men.</p><p>Patients often have <strong>autoantibodies</strong> such as ANA, anti-smooth muscle antibodies, and anti-LKM1.</p><p><strong>Neurological symptoms</strong> are uncommon in autoimmune hepatitis, and the hallmark <strong>Kayser-Fleischer ring</strong> is not associated with this condition. In autoimmune hepatitis, serum ceruloplasmin and urinary copper levels would not be altered as they are in Wilson's disease.</p><p><strong>Option D: Alpha-1 antitrypsin deficiency</strong></p><p>Alpha-1 antitrypsin (AAT) deficiency primarily affects the <strong>lungs</strong> (causing emphysema) and the <strong>liver</strong> (causing cirrhosis). While it can present with <strong>liver disease</strong> and elevated liver enzymes, it does not cause <strong>neurological symptoms</strong> or <strong>Kayser-Fleischer rings</strong>.</p><p>AAT deficiency should be suspected in patients with early-onset emphysema, especially in nonsmokers, and liver disease, but it lacks the copper metabolism abnormalities seen in Wilson's disease.</p><p><strong>Differential Diagnosis:</strong></p><ol><li><strong>Hemochromatosis</strong> - Iron overload disorder with hepatic and endocrine involvement but no neurological or ocular signs.</li><li><strong>Autoimmune hepatitis</strong> - Liver disease associated with autoantibodies and immune dysfunction, but without copper metabolism abnormalities.</li><li><strong>Alpha-1 antitrypsin deficiency</strong> - A genetic disorder affecting the liver and lungs, but it does not involve copper metabolism or neurological symptoms.</li></ol><p><strong>Key to Remember/Mnemonics:</strong></p><ul><li><strong>Wilson's disease mnemonic: \"Copper HELL\"</strong></li></ul><ul><ul><li><strong>C</strong>opper accumulation</li><li><strong>H</strong>epatolenticular degeneration</li><li><strong>E</strong>yes (Kayser-Fleischer rings)</li><li><strong>L</strong>ow ceruloplasmin</li><li><strong>L</strong>iver disease and neurological symptoms</li></ul></ul><ul><li><strong>Diagnosis:</strong> Low <strong>serum ceruloplasmin</strong>, high <strong>urinary copper</strong>, and <strong>Kayser-Fleischer rings</strong>.</li></ul><p><strong>Topic:</strong> Intermediary metabolism:Wilson's disease</p><p><strong>Difficulty Level:</strong> Must Know</p><p><strong>PYQ:</strong> FMGE 2020/2021/2022 NEET 2020, INICET 2022</p><p><strong>Reference:</strong> Harrison's principles of internal medicine, 21<sup>st</sup> edition, Page Number 3236</p>",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Elevated fasting glucose, increased BMI, and high triglycerides</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased waist circumference, elevated fasting glucose, and low HDL cholesterol</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Elevated blood pressure, increased BMI, and low HDL cholesterol</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased waist circumference, elevated fasting glucose, and high LDL cholesterol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old man presents for a routine health check-up. His BMI is 32 kg/m2, waist circumference is 110 cm, fasting glucose is 130 mg/dL, blood pressure is 150/90 mmHg, triglycerides are 210 mg/dL, and HDL cholesterol is 35 mg/dL. Which of the following criteria confirms the diagnosis of metabolic syndrome?</span></p>",
      "unique_key": "Q240613",
      "question_audio": null,
      "question_video": null,
      "map_id": 240613,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p>Metabolic syndrome is diagnosed when at least <strong>three out of five criteria</strong> are present:</p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/8E.jpg\"><p>In this patient:</p><ul><li>Waist circumference: <strong>110 cm</strong> (meets criteria).</li><li>Fasting glucose: <strong>130 mg/dL</strong> (meets criteria).</li><li>HDL cholesterol: <strong>35 mg/dL</strong> (meets criteria).</li></ul><p><strong>Option A:</strong> BMI is not a direct criterion; waist circumference is. High triglycerides are correct, but this does not meet the exact diagnostic criteria.</p><p><strong>Option B:</strong> This option correctly identifies three diagnostic criteria for metabolic syndrome.</p><p><strong>Option C:</strong> BMI is not a direct criterion. While blood pressure and low HDL are relevant, increased waist circumference is essential for diagnosis.</p><p><strong>Option D:</strong> LDL cholesterol is not a diagnostic criterion for metabolic syndrome.</p><p><strong>Easy Way to Remember/Key Fact to Remember:</strong></p><p><strong>\"Weigh Triglycerides Before Diagnosing HDL\"</strong></p><ul><li><strong>W</strong>: Waist circumference</li><li><strong>T</strong>: Triglycerides</li><li><strong>B</strong>: Blood pressure</li><li><strong>D</strong>: Dysglycemia (fasting glucose)</li><li><strong>H</strong>: HDL cholesterol</li></ul><p><strong>Topic Name:</strong> Metabolic Syndrome</p><p><strong>Difficulty Level:</strong> Must know</p><p><strong>PYQ:</strong> NEET PG 2020/2022</p><p><strong>Reference:</strong> Harrison's Principles of Internal Medicine, 21st Edition, Page Number:3151</p>",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Propranolol</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Phenoxybenzamine</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Clonidine</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Labetalol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 40-year-old man presents with episodic palpitations, sweating, headaches, and uncontrolled hypertension. His plasma free metanephrines are elevated. Before undergoing surgical removal of the suspected pheochromocytoma, which medication should be administered first to prevent perioperative complications?</span></p>",
      "unique_key": "Q240614",
      "question_audio": null,
      "question_video": null,
      "map_id": 240614,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p><strong>Complete tumor removal, the ultimate therapeutic goal, can be achieved by partial or total adrenalectomy. It is important to preserve the normal adrenal cortex in order to prevent Addison's disease, particularly in hereditary disorders in which bilateral pheochromocytomas are most likely.</strong></p><p>Preoperative preparation of the patient has to be considered, and blood pressure should be consistently &lt;160/90 mmHg. Classically, blood pressure has been controlled by &alpha;-adrenergic blockers (oral phenoxybenzamine, 0.5-4 mg/kg of body weight).</p><p>Because patients are volume constricted, liberal salt intake and hydration are necessary to avoid severe orthostasis. Oral prazosin or intravenous phentolamine can be used to manage paroxysms while adequate alpha blockade is awaited.</p><p>Beta blockers (e.g., 10 mg of propranolol three or four times per day) can then be added. Other antihypertensives, such as calcium channel blockers or angiotensin-converting enzyme inhibitors, have also been used effectively.</p><p>The primary concern in pheochromocytoma surgery is preventing hypertensive crises due to catecholamine release from the tumor. <strong>Phenoxybenzamine</strong>, an irreversible non-selective alpha-blocker, is given first to achieve adequate alpha-adrenergic blockade. This prevents vasoconstriction and reduces the risk of hypertensive episodes during surgery.</p><p><strong>Option A: Propranolol:</strong>Beta-blockers are used only after adequate alpha-blockade to prevent unopposed alpha-adrenergic stimulation, which can lead to severe hypertension.</p><p><strong>Option B: Phenoxybenzamine:</strong>As an alpha-blocker, it reduces vasoconstriction and stabilizes blood pressure, making it the first choice for preoperative management of pheochromocytoma.</p><p><strong>Option C: Clonidine:</strong>Although it lowers catecholamine levels, clonidine is not the standard therapy for pheochromocytoma-related hypertension.</p><p><strong>Option D: Labetalol:</strong>Labetalol has both alpha- and beta-blocking effects but is less effective than phenoxybenzamine in achieving complete alpha blockade and is not the preferred first-line agent.</p><p><strong>Differential Diagnosis for Hypertension with Episodic Symptoms:</strong></p><ol><li><strong>Essential Hypertension</strong>: No episodic nature or metanephrine elevation.</li><li><strong>Hyperthyroidism</strong>: Palpitations and sweating without hypertension spikes.</li><li><strong>Carcinoid Syndrome</strong>: Flushing and diarrhea, no significant hypertension.</li><li><strong>Renal Artery Stenosis</strong>: Persistent hypertension without catecholamine excess.</li></ol><p><strong>Easy Way to Remember/Key Fact to Remember:</strong></p><p><strong>\"Alpha before Beta in Pheochromocytoma\"</strong> Always start with an alpha-blocker (phenoxybenzamine) before adding beta-blockers to avoid unopposed alpha stimulation.</p><p><strong>Topic Name:</strong> Pheochromocytoma - Preoperative Management</p><p><strong>Difficulty Level:</strong> Must know</p><p><strong>PYQ:</strong> NEET PG 2021 FMGE 2020,2021</p><p><strong>Reference:</strong> <em><strong>Harrison's Principles of Internal Medicine, 21st Edition,</strong></em> Page Number:2979</p>",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Primary polydipsia</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Central diabetes insipidus</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Nephrogenic diabetes insipidus</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 30-year-old woman presents with excessive thirst and polyuria producing 6 liters of dilute urine daily. Serum sodium is 150 mmol/L, and urine osmolality is 100 mOsm/kg. A water deprivation test is performed, and urine osmolality remains low despite dehydration. However, urine osmolality increases significantly after the administration of desmopressin. What is the most likely diagnosis?</span></p>",
      "unique_key": "Q240615",
      "question_audio": null,
      "question_video": null,
      "map_id": 240615,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p>The patient&rsquo;s clinical features and laboratory findings point towards diabetes insipidus (DI). The water deprivation test helps differentiate between central and nephrogenic DI:</p><ul><li>In <strong>central DI</strong>, there is a deficiency of antidiuretic hormone (ADH). Desmopressin, an ADH analog, will cause a significant increase in urine osmolality.</li><li>In <strong>nephrogenic DI</strong>, the kidneys are unresponsive to ADH, so desmopressin has little or no effect.</li></ul><p>This patient's urine osmolality increased after desmopressin, confirming <strong>central diabetes insipidus</strong>.</p><p><strong>Option A: Primary polydipsia:</strong>Characterized by excessive water intake, leading to dilute urine. Urine osmolality increases after water deprivation as ADH secretion is intact. Desmopressin does not significantly increase urine osmolality.</p><p><strong>Option B: Central diabetes insipidus:</strong>Caused by a lack of ADH production or secretion. Urine osmolality increases significantly after desmopressin administration.</p><p><strong>Option C: Nephrogenic diabetes insipidus:</strong>ADH is produced but the kidneys are resistant. Urine osmolality does not increase significantly after desmopressin administration.</p><p><strong>Option D: Syndrome of inappropriate antidiuretic hormone secretion (SIADH):</strong>Characterized by inappropriate ADH secretion, causing concentrated urine and hyponatremia. This patient has dilute urine and hypernatremia, ruling out SIADH.</p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/10E.jpg\"><p><strong>Differential Diagnosis for Polyuria and Polydipsia:</strong></p><ol><li><strong>Primary Polydipsia:</strong> Psychogenic water consumption, normal response to water deprivation.</li><li><strong>Central DI:</strong> Reduced ADH secretion, positive response to desmopressin.</li><li><strong>Nephrogenic DI:</strong> Resistance to ADH, no significant response to desmopressin.</li><li><strong>Diabetes Mellitus:</strong> Osmotic diuresis from hyperglycemia.</li></ol><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/10E1.jpg\"><p><strong>Easy Way to Remember/Key Fact to Remember:</strong></p><p><strong>\"Central = Correctable\"</strong> Central DI responds to desmopressin because the issue lies in ADH production, not kidney response.</p><p><strong>Topic Name:</strong>Diabetes Insipidus</p><p><strong>Difficulty Level:</strong> Must know</p><p><strong>PYQ:</strong> NEET PG 2020,2023,FMGE 2020</p><p><strong>Reference:</strong> <em><strong>Harrison's Principles of Internal Medicine, 21st Edition,</strong></em> Page Number. 2922</p>",
      "correct_choice_id": 92,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Alendronate</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcitonin</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Teriparatide</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Denosumab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65-year-old postmenopausal woman presents with a history of recurrent fractures and a T-score of -3.0 on a dual-energy X-ray absorptiometry (DEXA) scan. She is diagnosed with severe osteoporosis. Which of the following is the most appropriate first-line pharmacological treatment for her condition?</span></p>",
      "unique_key": "Q240616",
      "question_audio": null,
      "question_video": null,
      "map_id": 240616,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p>Osteoporosis treatment aims to reduce the risk of fractures and improve bone density.</p><ul><li><strong>Bisphosphonates (e.g., Alendronate):</strong> First-line treatment due to their proven efficacy in reducing vertebral and non-vertebral fractures. They inhibit osteoclast-mediated bone resorption and are suitable for long-term use in postmenopausal osteoporosis.</li><li><strong>Other agents:</strong> Considered based on patient-specific factors such as intolerance to bisphosphonates or contraindications.</li></ul><p><strong>Option A: Alendronate</strong></p><p>A bisphosphonate that significantly reduces fracture risk by inhibiting bone resorption. It is the first-line treatment for postmenopausal women with osteoporosis.</p><p><strong>Option B: Calcitonin</strong></p><p>Not a first-line therapy. It has a modest effect on bone density and is primarily used for acute pain relief in vertebral fractures.</p><p><strong>Option C: Teriparatide</strong></p><p>A parathyroid hormone analog that stimulates bone formation. Reserved for severe osteoporosis or patients who fail other therapies.</p><p><strong>Option D: Denosumab</strong></p><p>A monoclonal antibody against RANKL that inhibits osteoclast activity. Useful in patients intolerant to bisphosphonates or with renal impairment.</p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/11E.jpg\"><p><strong>Differential Diagnosis for Treatment Options:</strong></p><ol><li><strong>Bisphosphonates:</strong> First-line agents unless contraindicated.</li><li><strong>Teriparatide:</strong> Used for severe osteoporosis or failure of first-line therapies.</li><li><strong>Denosumab:</strong> Suitable for patients with renal impairment or bisphosphonate intolerance.</li><li><strong>Calcitonin:</strong> Limited use for pain relief in acute fractures.</li></ol><p><strong>Easy Way to Remember/Key Fact to Remember:</strong></p><p><strong>\"Bisphosphonates Build Bones Before Others\"</strong></p><ul><li>Start with bisphosphonates (e.g., Alendronate) for most cases of osteoporosis.</li><li>Escalate to advanced therapies like Teriparatide or Denosumab if needed.</li></ul><p><strong>Topic Name:</strong> Treatment of Osteoporosis</p><p><strong>Difficulty Level:</strong> May know</p><p><strong>PYQ:</strong> NEET PG 2020</p><p><strong>Reference:</strong> <em>Harrison's Principles of Internal Medicine, 21st Edition,</em> Page Number. 3205</p>",
      "correct_choice_id": 101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Observation and conservative management with high-dose glucocorticoids</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Immediate administration of dopamine agonists</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Urgent surgical decompression</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Long-term hormone replacement therapy only</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is the most appropriate management for a patient with pituitary apoplexy presenting with severe visual loss and ophthalmoplegia?</span></p>",
      "unique_key": "Q240617",
      "question_audio": null,
      "question_video": null,
      "map_id": 240617,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p><strong>A. Observation and conservative management with high-dose glucocorticoids</strong></p><ul><li>Observation and high-dose glucocorticoids are appropriate for patients with no visual loss or impaired consciousness. However, this approach is insufficient for cases with significant visual loss, cranial nerve palsies, or other severe complications requiring immediate intervention.</li><li><strong>Incorrect</strong> for patients with severe visual loss and ophthalmoplegia.</li></ul><p><strong>B. Immediate administration of dopamine agonists</strong></p><ul><li>Dopamine agonists are used in prolactinoma management but are not indicated for acute pituitary apoplexy, especially in emergency cases with visual impairment.</li><li><strong>Incorrect</strong> in the context of pituitary apoplexy.</li></ul><p><strong>C. Urgent surgical decompression</strong></p><ul><li>This is the definitive treatment for patients with severe or progressive visual deficits, cranial nerve palsies, or altered consciousness due to pituitary apoplexy. Surgery aims to relieve the pressure on adjacent structures and prevent irreversible damage.</li><li>Visual recovery is time-sensitive; early surgical intervention improves outcomes.</li><li><strong>Correct</strong> for the given scenario.</li></ul><p><strong>D. Long-term hormone replacement therapy only</strong></p><ul><li>While hormone replacement is necessary to manage hypopituitarism following pituitary apoplexy, it does not address the acute need for decompression in severe cases.</li><li><strong>Incorrect</strong> for immediate management.</li></ul><p><strong>Differential Diagnosis</strong>: Sheehan&rsquo;s syndrome, meningitis, subarachnoid hemorrhage, cavernous sinus thrombosis, prolactinoma with hemorrhage.</p><p><strong>Key to Remember</strong>:</p><ul><li>Severe headache + ophthalmoplegia + visual loss &rarr; Think pituitary apoplexy.</li><li><strong>Urgent decompression</strong> is essential if severe visual or neurological symptoms are present.</li></ul><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/12E.jpg\"><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/12E1.jpg\"><p><strong>Topic Name:</strong>Pituitary Apoplexy</p><p><strong>Difficulty Level;</strong><strong>May know</strong></p><p><strong>PYQ:</strong><strong>NEET 2020</strong></p><p><strong>Reference:</strong> Harrison's Principles of Internal Medicine, 21st Edition, Page number:2897</p>",
      "correct_choice_id": 113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Ectopic ACTH syndrome</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Adrenocortical adenoma</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Adrenocortical carcinoma</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Cushing's disease</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is the most common cause of ACTH-dependent Cushing's syndrome?</span></p>",
      "unique_key": "Q240618",
      "question_audio": null,
      "question_video": null,
      "map_id": 240618,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p><strong>A. Ectopic ACTH syndrome</strong></p><ul><li>Accounts for <strong>15%</strong> of ACTH-dependent Cushing's syndrome.</li><li>Caused by ACTH secretion from non-pituitary tumors (e.g., <strong>small-cell lung cancer, carcinoid tumors).</strong></li></ul><p><strong>B. Adrenocortical adenoma</strong></p><ul><li>Represents a cause of ACTH-independent Cushing's syndrome, contributing <strong>5-10% </strong>of cases.</li></ul><p><strong>C. Adrenocortical carcinoma</strong></p><ul><li>A rare cause (&lt;1%) of ACTH-independent Cushing's syndrome.</li></ul><p><strong>D. Cushing's disease</strong></p><ul><li>Caused by ACTH-secreting pituitary adenomas.</li><li>Responsible for <strong>75%</strong> of ACTH-dependent Cushing's syndrome.</li><li>it is the most common cause of cushing syndrome</li></ul><p><strong>Differential Diagnosis/Key to Remember/Easy Way to Remember</strong></p><ul><li><strong>ACTH-Dependent Cushing's Syndrome</strong>: Cushing's disease &gt; Ectopic ACTH.</li><li><strong>ACTH-Independent Cushing's Syndrome</strong>: Adrenocortical adenoma &gt; Adrenocortical carcinoma.</li></ul><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/13E.jpg\"><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/13E1.jpg\"><p><strong>Topic Name: </strong>Cushing syndrome</p><p><strong>Difficulty Level: </strong>May know</p><p><strong>PYQ:</strong> NEET 2020</p><p><strong>Reference:</strong> Harrison's Principles of Internal Medicine, 21st Edition, Page number:2960</p>",
      "correct_choice_id": 124,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Insulin</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Sulfonylureas (e.g., Glimepiride)</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Dapagliflozin</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Liraglutide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old woman with a history of type 2 diabetes presents with complaints of unexplained weight gain and fasting blood glucose levels consistently above 200 mg/dL. She is currently on metformin but has not achieved adequate glycemic control. Physical examination reveals a BMI of 32 kg/m&#178; and no signs of renal impairment. Which of the following drugs would be the best next step in her management?</span></p>",
      "unique_key": "Q240619",
      "question_audio": null,
      "question_video": null,
      "map_id": 240619,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p><strong>A. Insulin</strong></p><ul><li><strong>Mechanism</strong>: Directly reduces blood glucose levels by promoting glucose uptake.</li><li><strong>Reason for exclusion</strong>: Insulin is usually reserved for patients with severe hyperglycemia, signs of ketosis, or advanced disease. It may also promote weight gain, which is undesirable in this patient with a high BMI.</li></ul><p><strong>B. Sulfonylureas (e.g., Glimepiride)</strong></p><ul><li><strong>Mechanism</strong>: Stimulates insulin secretion from pancreatic beta cells.</li><li><strong>Reason for exclusion</strong>: Effective but may cause weight gain and a risk of hypoglycemia, especially in overweight patients.</li></ul><p><strong>C. Dapagliflozin</strong></p><ul><li><strong>Mechanism</strong>: SGLT2 inhibitor that promotes glucose excretion via the kidneys.</li><li><strong>Reason for exclusion</strong>: Effective in improving glycemic control and reducing weight, but GLP-1 receptor agonists like liraglutide offer superior weight loss and glycemic benefits in obese patients.</li></ul><p><strong>D. Liraglutide</strong></p><ul><li><strong>Mechanism</strong>: GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and promotes weight loss.</li><li><strong>Reason for inclusion</strong>: Most appropriate for this patient due to its dual benefit of weight loss and glycemic control. It is particularly effective in patients with obesity and inadequately controlled diabetes.</li></ul><p><strong>Differential Diagnosis/Key to Remember/Easy Way to Remember</strong></p><ul><li><strong>Key to Remember</strong>:<ul><li>GLP-1 receptor agonists (e.g., liraglutide) are preferred in obese patients due to <strong>weight loss benefits</strong>.</li><li>SGLT2 inhibitors (e.g., dapagliflozin) are a good alternative but may be less effective for weight loss compared to GLP-1 agonists.</li><li>Sulfonylureas and insulin may lead to <strong>weight gain</strong>, which is undesirable in this scenario.</li></ul></li></ul><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/14E1.jpg\"><p><strong>Topic Name:</strong> Diabetes mellitus:Anti-diabetic drugs</p><p><strong>Difficulty Level:</strong> May know</p><p><strong>PYQ:</strong> NEET 2022 FMGE 2022,2023 INI CET 2022</p><p><strong>Reference:</strong> Harrison's Principles of Internal Medicine, 21st Edition, Page number: 3110</p>",
      "correct_choice_id": 134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Streak gonads</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Gynecomastia</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Webbed neck</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Cyclical hematuria</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is a characteristic feature of Klinefelter syndrome (47, XXY)?</span></p>",
      "unique_key": "Q240620",
      "question_audio": null,
      "question_video": null,
      "map_id": 240620,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000010
      ],
      "solution": "<p><strong>A. Streak Gonads</strong></p><ul><li><strong>Feature</strong>: Streak gonads refer to non-functional fibrous tissue in place of ovaries or testes, commonly seen in Turner syndrome (45,X or mosaicism).</li><li><strong>Association</strong>: Turner syndrome is characterized by features such as webbed neck, short stature, cardiac defects, and primary amenorrhea.</li><li>Klinefelter syndrome (47,XXY) is characterized by small, firm testes with seminiferous tubule hyalinization, not streak gonads.</li></ul><p><strong>B. Gynecomastia</strong></p><ul><li><strong>Feature</strong>: Gynecomastia is a hallmark of Klinefelter syndrome due to increased estradiol levels and reduced testosterone levels caused by primary gonadal insufficiency.</li><li><strong>Mechanism</strong>: Elevated estradiol relative to testosterone leads to breast tissue development in phenotypic males.</li><li><strong>Clinical Implications</strong>: Increases the risk of breast cancer in Klinefelter syndrome.</li><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/15E.jpg\"></ul><p><strong>C. Webbed Neck</strong></p><ul><li><strong>Feature</strong>: Webbed neck is a classical feature of Turner syndrome (45,X), caused by congenital lymphedema and failure of normal lymphatic development.</li><li><strong>Association</strong>: Often seen with other features like low hairline, shield chest, and short stature.</li><li>Klinefelter syndrome does not present with webbed neck.</li></ul><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/15E1.jpg\"><p><strong>D. Cyclical Hematuria</strong></p><ul><li><strong>Feature</strong>: Cyclical hematuria is seen in ovotesticular DSD, where both ovarian and testicular tissues are present. It occurs due to menstruation-like bleeding in individuals with functional uterine tissue.</li><li><strong>Association</strong>: Typically seen in individuals with ambiguous genitalia or a mixed gonadal structure.</li><li>Klinefelter syndrome does not involve ovotesticular features or ambiguous genitalia.</li></ul><p>Key to remember</p><ul><li><strong>Klinefelter Syndrome (47,XXY)</strong>: Gynecomastia, small testes, tall stature, infertility, increased estradiol.</li><li><strong>Turner Syndrome (45,X)</strong>: Streak gonads, webbed neck, short stature, primary amenorrhea.</li><li><strong>Ovotesticular DSD</strong>: Cyclical hematuria, ambiguous genitalia, ovarian/testicular tissue</li></ul><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizDec2024/MedicineMiiVii13122024/15E2.jpg\"><p><strong>Topic Name:</strong> Disorders of sex developement</p><p><strong>Difficulty Level:</strong> May know</p><p><strong>PYQ:</strong> INI CET 2021</p><p><strong>Reference:</strong> Harrison's Principles of Internal Medicine, 21st Edition, Page Number:3001</p>",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}